Palisade Bio (PALI) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Palisade Bio (PALI) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 100.14% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 56.79% |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | -318.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -318.44% |
| Mar 31, 2026 | -66.74% |
| Dec 31, 2025 | -32.05% |
| Sep 30, 2025 | -13.41% |
| Jun 30, 2025 | 48.07% |
| Mar 31, 2025 | 26.64% |
| Dec 31, 2024 | 13.29% |
| Sep 30, 2024 | -17.69% |
| Jun 30, 2024 | -59.12% |
| Mar 31, 2024 | 9.81% |
| Dec 31, 2023 | 16.94% |
| Sep 30, 2023 | 12.43% |
| Jun 30, 2023 | 32.34% |
| Mar 31, 2023 | 6.32% |
| Dec 31, 2022 | -8.22% |
| Sep 30, 2022 | -10.71% |
| Jun 30, 2022 | 57.91% |
| Mar 31, 2022 | -201.12% |
| Dec 31, 2021 | -97.35% |
| Sep 30, 2021 | -216.00% |